Pembrolizumab, in addition to chemotherapy, is in clinical development for adults with urothelial cancer that is advanced or metastatic. Urothelial cancer occurs on the lining of the bladder and other parts of the urinary system. In advanced urothelial cancer, the cancer has grown into deeper layers including connective tissue or muscle. In metastatic urothelial cancer, the cancer has spread to other parts of the body, such as the liver or bones. Urothelial cancer usually occurs in patients aged 60 years and older, and many patients have other medical conditions, or are not fit enough to be given certain treatments.
Pembrolizumab is a drug administered by intravenous infusion which stimulates the body’s own immune system to fight cancer cells. If licensed, pembrolizumab in addition to chemotherapy could provide an additional or alternative treatment option to patients who currently have limited treatment options.
Atezolizumab is a cancer medicine that enhances T-cell (part of the immune system) activity against tumours. Nab-paclitaxel is a chemotherapy that combines the chemotherapy drug paclitaxel with a protein called albumin. It inhibits cell growth by preventing cell division. The combination may offer an additional neoadjuvant treatment option to improve clinical efficacy in the treatment of people with early stage TNBC, an aggressive disease with no approved targeted therapy.